Last modified by Wilton Risenhoover on 2022/07/01 19:35
From version < 4.2 >
edited by Asif Farooqui
on 2021/03/29 13:41
To version < 5.1 >
edited by Asif Farooqui
on 2021/03/29 13:42
< >
Change comment: There is no comment for this version

Summary

Details

Page properties
Content
... ... @@ -16,6 +16,10 @@
16 16  
17 17  The new Eltroxin manufacturing facility in its current Nashik site became operational recently.
18 18  
19 +
20 +[[image:GLAXO.jpg]]
21 +
22 +
19 19  == Global R&D support groups in Bengaluru, Karnataka ==
20 20  
21 21  Global Regulatory Platforms and Delivery (GRPD): GRPD is a regulatory affairs function that brings together critical capabilities for GSK, such as regulatory dossier production, regulatory life cycle management, global labeling and regulatory information management.
... ... @@ -92,6 +92,17 @@
92 92  
93 93  The Q4 has presented to it an unprecedented challenge in the form of a global pandemic. At GSK, its core guiding principles remains employee safety and well-being, business continuity, and social responsibility. As the nation-wide lockdown is getting relaxed, GSK is swiftly adapting to news ways of working defined by self-assessment, social distancing and good hygiene practices. As a socially responsible corporate citizen, GlaxoSmithKline Pharmaceuticals has contributed essential medicines and PPEs to the state government of Maharashtra and have committed funds to the PM-CARES.”
94 94  
99 +
100 +**GlaxoSmithKline Consolidated December 2020 Net Sales at Rs 857.20 crore, up 10.1% Y-o-Y **{{footnote}}https://www.moneycontrol.com/news/business/earnings/glaxosmithkline-consolidated-december-2020-net-sales-at-rs-857-20-crore-up-10-1-y-o-y-6475341.html{{/footnote}}
101 +
102 +**February 09, 2021; **Reported Consolidated quarterly numbers for GlaxoSmithKline Pharmaceuticals are:
103 +
104 +* Net Sales at Rs 857.20 crore in December 2020 up 10.1% from Rs. 778.59 crore in December 2019.
105 +* Quarterly Net Profit at Rs. 156.51 crore in December 2020 up 123.67% from Rs. 661.16 crore in December 2019.
106 +* EBITDA stands at Rs. 219.53 crore in December 2020 up 55.82% from Rs. 140.89 crore in December 2019.
107 +* GlaxoSmithKline EPS has increased to Rs. 9.24 in December 2020 from Rs. 39.03 in December 2019.
108 +
109 +
95 95  = References =
96 96  
97 97  {{putFootnotes/}}
This site is funded and maintained by Fintel.io